Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Homozygous Familial Hypercholesterolemia
2017-000351-95Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Alirocumab 150 mg Q2W with Placebo Q2W (2 arms). Primary endpoint: Percent change in LDL-C from baseline to week 12. Started Jun 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2017-000351-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000351-95.